文献速递流行病学与生物统计真实世界研究与卫生经济

皮肤癌筛查:美国预防服务工作组更新证据报告与系统综述

Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2023-01-01

本系统综述纳入20项研究(N=6 053 411),评估皮肤癌筛查的获益与危害。非随机证据提示早期发现与死亡率降低相关,但基于德国人群筛查项目的非随机分析未显示黑色素瘤死亡率获益,常规临床皮肤检查与更早期黑色素瘤检出无关联。

要点

  • 德国人群筛查项目的非随机分析未显示黑色素瘤死亡率获益。
  • 常规临床皮肤检查与更早期黑色素瘤检出无关联。
  • 更晚期黑色素瘤与黑色素瘤相关及全因死亡风险升高一致相关。

核心结论

  • 大量非随机证据提示皮肤癌检出时分期越早与死亡风险降低明确相关,但非随机研究提示视觉皮肤检查筛查对青少年或成人黑色素瘤死亡率获益很小至无获益,且常规临床皮肤检查与更早期黑色素瘤检出无关联。
  • 临床皮肤检查是否与检出时更薄的黑色素瘤病灶相关,证据不一致。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials自2015年6月1日至2022年1月7日,监测至2022年12月16日。
  • 纳入在15岁及以上无症状人群中开展的英文研究,共纳入20项研究(29篇文章,N=6 053 411)。
  • 由两名评价者独立评估文献并提取质量中等或良好研究的相关数据,结果采用叙述性总结。

主要发现

  • 筛查有效性的直接证据来自德国2个基于人群的皮肤癌筛查项目的3项非随机分析(n=1 791 615),随访4至10年,提示在人群水平无黑色素瘤死亡率获益。
  • 6项研究(n=2 935 513)关于临床医生皮肤检查与诊断时病灶厚度或分期的关联,证据不一致。
  • 与常规医疗相比,常规临床医生皮肤检查与皮肤癌或前驱病变检出增加无关联(5项研究),与黑色素瘤检出时分期也无关联(3项研究);临床医生皮肤检查与检出时病灶厚度的关联证据不一致(3项研究)。
  • 9项研究(n=1 326 051)发现黑色素瘤检出时分期越晚,黑色素瘤相关死亡和全因死亡风险升高呈一致正相关。
  • 2项研究(n=232)发现筛查与持续性美容或心理社会危害几乎无关联至无关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Skin cancer is the most common cancer type and is a major cause of morbidity. OBJECTIVE: To systematically review the benefits and harms of screening for skin cancer to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from June 1, 2015, through January 7, 2022; surveillance through December 16, 2022. STUDY SELECTION: English-language studies conducted in asymptomatic populations 15 years or older. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently appraised the articles and extracted relevant data from fair- or good-quality studies; results were narratively summarized. MAIN OUTCOMES AND MEASURES: Morbidity; mortality; skin cancer stage, precursor lesions, or lesion thickness at detection; harms of screening. RESULTS: Twenty studies in 29 articles were included (N = 6 053 411). Direct evidence on screening effectiveness was from 3 nonrandomized analyses of 2 population-based skin cancer screening programs in Germany (n = 1 791 615) and suggested no melanoma mortality benefit at the population level over 4 to 10 years' follow-up. Six studies (n = 2 935 513) provided inconsistent evidence on the association between clinician skin examination and lesion thickness or stage at diagnosis. Compared with usual care, routine clinician skin examination was not associated with increased detection of skin cancer or precursor lesions (5 studies) or stage at melanoma detection (3 studies). Evidence on the association between clinician skin examination and lesion thickness at detection was inconsistent (3 studies). Nine studies (n = 1 326 051) found a consistent positive association between more advanced stage at melanoma detection and increasing risk of melanoma-associated and all-cause mortality. Two studies (n = 232) found little to no persistent cosmetic or psychosocial harms associated with screening. CONCLUSIONS AND RELEVANCE: A substantial nonrandomized evidence base suggests a clear association between earlier stage at skin cancer detection and decreased mortality risk. However, nonrandomized studies suggest little to no melanoma mortality benefit associated with skin cancer screening with visual skin examination in adolescents or adults and no association between routine clinician skin examination and earlier stage at melanoma detection. Evidence is inconsistent regarding whether clinician skin examination is associated with thinner melanoma lesions at detection.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Henrikson NB, Ivlev I, Blasi PR, et al. Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023. PMID: 37071090. doi:10.1001/jama.2023.3262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。